Todd Chapin, PharmD, BCPS @SanfordHealth #AtrialFibrillation #Cardiology #Heart #Research Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Todd Chapin, PharmD, BCPS @SanfordHealth #AtrialFibrillation #Cardiology #Heart #Research Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

User Photo
CardiologyNews

3 months
28 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Todd Chapin, PharmD, BCPS from Sanford Health speaks about Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation.

Link to Study:
https://clinicaltrials.gov/ct2/show/NCT02889562?recrs=dem&cond=Atrial+Fibrillation&cntry=US&phase=123&draw=2&rank=51

Patients who experience atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified in this open-label, prospective, randomized pilot study. Patients with chronic prolonged atrial fibrillation (>2 episodes of atrial fibrillation lasting longer than 30 minutes) or persistent atrial fibrillation (>12 hours) would be qualified. Patients will be randomized to either the standard of care (warfarin per protocol) or the apixaban arms of the trial after meeting research inclusion and exclusion requirements and giving informed consent. Both groups will receive routine postoperative treatment after CABG. The anticoagulation clinic will treat anticoagulation in both classes after discharge. After surgery, patients will be monitored for 30 days.

Up Next Autoplay